Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

• Main Authors: Li Qiao, Deliang Ma, Hui Lv, Ding Shi, Min Fei, Yu Chen, Fei Xie, Zhuoyan Wang, Ying Wang, Wanhua Liang, Peiying Hu
• Format: Article
• Language: English
• Published: BMC 2020-10-01
• Series: Diabetology & Metabolic Syndrome
• Subjects: Metabolic syndrome; Lung cancer; Cohort study; Meta-analysis
• Online Access: http://link.springer.com/article/10.1186/s13098-020-00598-0

Abstract Background Metabolic syndrome (MetS) has been related to the pathogenesis of variety categories of cancers. This meta-analysis aimed to determine the association between MetS and the incidence of lung cancer. Methods Relevant cohort studies were identified by search of PubMed, Embase, and Cochrane’s Library databases. Cochrane’s Q test and I2 statistic were used to analyze the heterogeneity. Random-effect model which incorporates the potential heterogeneity was used for the meta-analysis. Results Five cohort studies with 188,970 participants were included. A total of 1,295 lung cancer cases occurred during follow-up. Meta-analyses showed that neither MetS defined by the revised NCEP-ATP III criteria (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.84 to 1.05, p = 0.25; I2 = 0) nor the IDF criteria (HR: 0.82, 95% CI: 0.61 to 1.11, p = 0.20; I2 = 0) was associated with an affected risk of lung cancer. Subgroup analyses showed consistent results in women and in men, in studies performed in Asian and non-Asian countries, and in prospective and retrospective cohorts (p all > 0.05). Meta-analysis limited to studies with the adjustment of smoking status also showed similar results (HR: 0.91, 95% CI: 0.80 to 1.05, p = 0.21; I2 = 0). No publication bias was detected based on the Egger regression test (p = 0.32). Conclusions Current evidence from cohort studies does not support that MetS is an independent risk factor for the incidence of lung cancer.